We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 30, 2021

Polypharmacy, High-Risk Drug Classes, and Adverse Health Outcomes With T1D



Additional Info

The Association of Polypharmacy and High-Risk Drug Classes With Adverse Health Outcomes in the Scottish Population With Type 1 Diabetes
Diabetologia 2021 Jun 01;64(6)1309-1319, A Höhn, A Jeyam, TM Caparrotta, SJ McGurnaghan, JE O'Reilly, LAK Blackbourn, RJ McCrimmon, GP Leese, JA McKnight, B Kennon, RS Lindsay, N Sattar, SH Wild, PM McKeigue, HM Colhoun, Scottish Diabetes Research Network (SDRN) Epidemiology Group

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading